ABLYNX ANNOUNCES HALF-YEAR RESULTS FOR 2013
(Thomson Reuters ONE) -
REGULATED INFORMATION
GHENT, Belgium, 21 August 2013 - Ablynx [Euronext Brussels: ABLX] today
announced its results for the six-month period ending 30 June 2013, which have
been prepared in accordance with the IAS 34 "Interim Financial Reporting" as
adopted by the European Union. Operational highlights are also reported.
Results will be discussed during a webcast presentation today at 11h CET, 5am
EST
Click here to register, call number +32 (0)2 404 06 62
Operational highlights - year-to-date 2013
* Reported excellent Phase IIa results with the anti-IL-6R Nanobody, ALX-
0061, in RA patients. Licensing discussions for this asset are progressing
with a number of pharmaceutical companies
* Entry criteria adapted for Phase II TITAN trial in TTP with caplacizumab
(anti-vWF Nanobody) to better facilitate recruitment
* Phase I study initiated by Merck Serono with the Nanobody, ALX-0761, for use
in inflammation
* Initiated additional Phase I studies with the anti-RSV Nanobody, ALX-0171
* Enhanced the internal pipeline with the start of pre-clinical development of
a potentially differentiated anti-IgE Nanobody, ALX-0962, to treat severe
allergic asthma
* Signed a research collaboration with Spirogen to evaluate the potential of
novel Nanobody-toxin drug conjugates in cancer
* Strengthened management team with appointment of a Chief Operating Officer,
a newly created role
* Appointment of Catherine Moukheibir as a new Independent Director of the
Company
Financial highlights - first six months ending June 30(th) 2013
* Raised ?31.5 million in a private placement of new shares
* Revenues of ?12.9 million (2012: ?16.6 million)
* Net loss for the period of ?10.5 million (2012: ?13.6 million)
* Positive net cash inflow of ?9.2 million, resulting in a strong financial
position of ?72.0 million in cash, cash equivalents, restricted cash and
short-term investments
Commenting on the half-year 2013 results, Dr Edwin Moses, Chairman and CEO of
Ablynx, said:
"We are pleased with the progress we have made during the first six months of
the year, both operationally and financially. The most significant news was the
announcement of excellent Phase IIa efficacy and safety data for our anti-IL-6R
Nanobody in rheumatoid arthritis patients. Discussions with a number of
interested pharmaceutical companies with the aim to license this Nanobody are
making good progress. We further enhanced our internal pipeline with earlier
stage assets, including the anti-IgE Nanobody, ALX-0962, to treat severe
allergic asthma. Our partner Merck Serono has also dosed the first healthy
volunteer in a Phase I study with the Nanobody, ALX-0761, for use in
inflammation."
"In addition to the clinical progress, we successfully raised ?31.5 million
through an over-subscribed private placement, which further improves our
flexibility to choose the right strategic options as well as expanding and
diversifying our shareholder base. The Company's free float increased to 65%."
"We look forward to enhancing our future growth prospects with six Nanobodies
currently in clinical development and a number of important product and
partnering catalysts expected during the remainder of the year."
Financial review
+----------------------------------+------------+------------+
| (? million) | H1 2013 | H1 2012 |
+----------------------------------+------------+------------+
| Revenues | 12.9 | 16.6 |
+----------------------------------+------------+------------+
| R&D income | 12.0 | 15.6 |
+----------------------------------+------------+------------+
| Grants | 0.9 | 1.0 |
+----------------------------------+------------+------------+
| Operating expenses | (23.8) | (30.6) |
+----------------------------------+------------+------------+
| R&D | (19.3) | (25.9) |
+----------------------------------+------------+------------+
| G&A | (4.5) | (4.7) |
+----------------------------------+------------+------------+
| Other operating income/(expense) | - | (0.3) |
+----------------------------------+------------+------------+
| Operating result | (10.9) | (14.4) |
+----------------------------------+------------+------------+
| Finance income (net) | 0.4 | 0.8 |
+----------------------------------+------------+------------+
| Net result | (10.5) | (13.6) |
+----------------------------------+------------+------------+
| |
+----------------------------------+------------+------------+
| Net cash inflow (burn) | 9.2 | (7.3) |
+----------------------------------+------------+------------+
| Cash at June 30(th) | 72.0 ((1)) | 76.5 ((2)) |
| | | |
+----------------------------------+------------+------------+
((1) )Including ?2.3 million in restricted cash
((2) )Including ?2.7 million restricted cash
About Ablynx
Ablynx is a biopharmaceutical company engaged in the discovery and development
of Nanobodies(®), a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has approximately 25 programmes in the pipeline and six Nanobodies at clinical
development stage. Ablynx has on-going research collaborations and significant
partnerships with major pharmaceutical companies including Boehringer Ingelheim,
Merck Serono, Novartis, Merck & Co. The Company is headquartered in Ghent,
Belgium.
More information can be found on www.ablynx.com.
For more information, please contact
Ablynx:
Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch(at)ablynx.com
Follow us on Twitter (at)AblynxABLX
Consilium Strategic Communications (spin-out from M:Communications):
Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 207 920 2345
e: ablynx(at)consilium-comms.com
complete version of the press release:
http://hugin.info/137912/R/1723964/574563.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Ablynx via Thomson Reuters ONE
[HUG#1723964]
Unternehmensinformation / Kurzprofil:
Datum: 21.08.2013 - 07:00 Uhr
Sprache: Deutsch
News-ID 289561
Anzahl Zeichen: 8177
contact information:
Town:
Ghent/Zwijnaarde
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 184 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX ANNOUNCES HALF-YEAR RESULTS FOR 2013"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
